India Pre-Market Regulatory Roundup — March 19, 2026

18-03-2026

Orchid Pharma Limited (symbol: ORCHPHARMA, scrip code: 524372) has provided an update under Regulation 30 of SEBI Listing Regulations stating that the Hon’ble National Company Law Tribunal (NCLT) has reserved its order on the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited for formal pronouncement on March 18, 2026. The company will notify stock exchanges and update its website upon receipt of the NCLT order copy. This follows earlier intimations on the pending merger petition.

• · CIN: L24222TN1992PLC022994
• · Contact: Phone (91)-44-27444471, Email: Corporate@orchidpharma

18-03-2026

Euro Pratik Sales Limited has intimated that a Board of Directors meeting is scheduled for March 23, 2026, to consider the declaration of an interim dividend on paid-up equity shares for FY 2025-26. The trading window for dealing in the company's securities is closed from March 18, 2026, till March 25, 2026, for directors and specified persons under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

• · Symbol: EUROPRATIK; Scrip Code: 544519
• · Membership No. of Company Secretary: A60044

18-03-2026

G R Infraprojects Limited has disclosed a proposed inter-se transfer of 21.00 L equity shares (2.17% of share capital) from Mr. Manish Gupta to Mrs. Shakuntala Devi Gupta, both promoter group members, by way of gift on or after March 25, 2026, at nil consideration. The transaction complies with SEBI SAST Regulation 10(5), remains below takeover thresholds, and will not change the aggregate promoter/promoter group shareholding or voting rights. Public shareholders' interests remain unaffected.

• · Disclosure filed on March 18, 2026, to BSE and NSE (Scrip Code: 543317, Symbol: GRINFRA).
• · Annexures confirm no encumbrances by promoters in FY 2022-23 (79.74% holding as on March 31, 2023), FY 2023-24, and FY 2024-25.

18-03-2026

Fortis Healthcare Limited shareholders approved three special resolutions via postal ballot on March 18, 2026, including the Employees Stock Option Scheme 2026 (96.59% assent), grants to subsidiary employees (96.70% assent), and grants to associate employees (87.58% assent with 12.42% dissent). All resolutions passed with requisite majority based on approximately 67.41 Cr shares voted. While approvals for the scheme and subsidiaries were overwhelmingly strong, the associate grant saw notably higher dissent.

• · Record date for voting eligibility: February 13, 2026.
• · E-voting closed at 5:00 PM IST on March 18, 2026.
• · Abstentions: ~1.01L to 7.74L shares across resolutions.
• · 3 postal ballots received via email.

18-03-2026

ArisInfra Solutions Limited (ARIS) approved the amalgamation of its 73.75%-owned subsidiary ArisUnitern RE Solutions Private Limited on March 18, 2026, with an appointed date of April 01, 2026, pending approvals from NCLT, SEBI, stock exchanges, and others. ArisUnitern showed strong revenue growth from ₹13 Cr in FY23 to ₹24.8 Cr in FY24 (91% YoY) and ₹43.2 Cr in FY25 (74% YoY), with ₹51.7 Cr revenue and ₹32.9 Cr PBT for the nine months ended December 2025. The merger will fully consolidate ArisUnitern's profits into ARIS, eliminating non-controlling interest and unlocking synergies in integration, cross-selling, and operational efficiency.

• · ARIS operates an asset-light, aggregator-led model with no inventory risk and minimal fixed assets.
• · Both businesses have shared customers, supply chains, and infrastructure since ArisUnitern's inception.
• · Post-merger benefits include EPS accretion, improved return ratios, and enhanced pricing power.

18-03-2026

Bharti Airtel Limited received ₹15,695.98 Cr (INR 156,959.77 million) towards the First and Final Call of ₹401.25 per share on 391,176,994 partly paid-up equity shares, converting them into fully paid-up shares of face value ₹5 each. This increases the total paid-up equity share capital to ₹30,467.80 Cr (INR 30,467,799,900), divided into 6,093,282,313 fully paid-up shares and 1,110,668 remaining partly paid-up shares. The converted shares will rank pari passu with existing shares and be listed on NSE and BSE upon approvals.

• · Partly paid-up shares bore ISIN IN9397D01014; fully paid-up under ISIN INE397D01024.
• · Company to issue reminder notices for unpaid calls on remaining 1,110,668 shares.

18-03-2026

CreditAccess Grameen Limited completed the issuance and allotment of 4,000 secured, rated, listed USD-denominated Non-Convertible Bonds aggregating USD 40,000,000, each with a face value of USD 10,000. The bonds have a 60-month tenure, are listed on NSE IFSC Limited, and offer a coupon of 240 basis points plus Term SOFR, payable half-yearly, secured by a charge on specific loan receivables. This follows an initial intimation on December 10, 2025.

• · Bonds secured by exclusive first ranking charge on present and future loan receivables/book debts via hypothecation deed.
• · Interest payments on half-yearly basis; principal as per Information Memorandum.
• · No delays in payments, no special rights/privileges, no redemption details applicable.

19-03-2026

Jonjua Overseas Limited submitted the Scrutinizer’s Report for its Extra Ordinary General Meeting (EGM) of equity shareholders held on March 18, 2026, at 04:30 P.M. in Mohali, Punjab. Shri Abhishek Gupta, Advocate, served as Scrutinizer, with a total of 31 shareholders present either in person or through proxy, including 7 from promoters and promoter group (1 via e-voting). Voting results were attached to the report, with no specific outcomes detailed in the filing.

• · EGM venue: 545 Jubilee Walk, Sector 70, Mohali 160071, Punjab
• · Trading Symbol: JONJUA; Scrip Code: 542446
• · CIN: L51909PB1993PLC013057
• · Report submitted to BSE Listing & Compliance Department on March 18, 2026